

OTHER TRANSACTION AGREEMENT (OTA)

OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)

BETWEEN

**Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6717**

AND

**THE UNITED STATES OF AMERICA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
200 C Street, S.W.
WASHINGTON, DC 20515**

CONCERNING

The research and development of a portfolio of new antibacterials to treat antibiotic resistant and
biothreat infections

HHSO100201700020C

Modification No. 0002

Date: April 22, 2019

Total Amount of the Agreement: \$23,366,518 (Unchanged)

Total Estimated Government Funding of the Agreement: \$18,693,213 (Unchanged)

Total Estimated Recipient Funding of the Agreement: \$4,673,305 (Unchanged)

Funds Obligated: \$18,693,213 (Unchanged)

Period of Performance: September 30, 2017 through June 30, 2021 (Unchanged)

Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness
Act, P.L. 109-417

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027
(b) (4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 199TWN
(b) (4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994047
(b) (4) (CLIN 0001).

Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994044
(b) (4) (CLIN 0001).

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027
(b) (4) (CLIN 0002)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 199TWLN
(b) (4) (CLIN 0003)

PURPOSE: The purpose of this modification is to provide a no cost extension for CLIN 0001.

Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

1. Under **ARTICLE II, PERIOD OF PERFORMANCE** is deleted and replaced as follows:

LINE ITEM	DESCRIPTION OF SERVICES	PERIOD OF PERFORMANCE
0001	Base Period-Generation and Isolation and characterization of lead mAbs and generation of (humanized) mouse model for PEP, EP and REP.	September 30, 2017 – May 31, 2019
0002	Option 1-PMPD Ab Production and In-Vivo testing of lead mAbs.	September 30, 2017-June 30, 2021
0003	Option 2-Toxicology Activities	September 30, 2017-May 31, 2021
0004	Option 3-IND enabling activities	June 30, 2019-May 31, 2021
0005	Option 4-Clinical study	July 31, 2021-November 30, 2023
0006	Option 5-Additional clinical study	November 30, 2023-March 31, 2026

All other terms and conditions remain the same.

FOR THE UNITED STATES OF AMERICA
OFFICE OF ACQUISITION MANAGEMENT,
CONTRACTS & GRANTS SECRETARY
FOR PREPAREDNESS AND RESPONSE

(b) (6)

4/25/19

(Signature)

(Date)

Carl A. Newman,
Other Transaction Agreement Officer

FOR Regeneron Pharmaceuticals INCORPORATED

(b) (6)

4/24/19

(Signature)

(Date)

Joseph J. LaRosa
Senior Vice President, Regeneron Pharmaceuticals, Inc.

END OF MODIFICATION No. 0002 TO HHSO100201700020C